1. This study assessed the application value of serum thymidine kinase 1 (TK1), PC cell-derived growth factor (PCDGF), cytokeratin 19 fragment 21-1 (CYFRA21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) plus enhanced CT scan in the diagnosis of nonsmall cell lung cancer (NSCLC) and chemotherapy monitoring.
2. The eligible patients had significantly higher serum levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA than those of the healthy individuals included.
3. Joint detection showed a larger area under the curve (AUC), a higher sensitivity, and a superior detection outcome to the stand-alone detection.
The article is generally reliable and trustworthy as it provides detailed information on the methods used in the study, such as sample collection, measurement of serum markers, enhanced CT scan, and outcome assessment. Furthermore, it also provides statistical analysis results for comparison between experimental group and control group. However, there are some potential biases that should be noted. Firstly, the sample size is relatively small with only 30 participants in each group which may not be sufficient to draw valid conclusions from this study. Secondly, there is no mention of any potential risks associated with using these tests or scans which could be important for patients to consider before undergoing them. Additionally, there is no discussion on possible counterarguments or alternative approaches that could be taken when diagnosing NSCLC which could provide more comprehensive insights into this topic. Finally, there is no mention of any conflicts of interest which could potentially influence the results presented in this article.